Generalized Anxiety Disorder (GAD) Clinical Trials

Find Generalized Anxiety Disorder (GAD) Clinical Trials Near You

Clinical Efficacy of Electroacupuncture for Generalized Anxiety Disorder and Its Central Mechanism Based on Neuroimaging Changes

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to evaluate the clinical efficacy and safety of electroacupuncture (EA) as an adjunctive treatment for generalized anxiety disorder (GAD). Participants in the clinical trial will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group. All participants in the clinical trial will receive monotherapy with one of three SSRIs: sertraline, paroxetine, or escitalopram, selected by a psychiatrist according to clinical suitability, previous treatment response, and tolerability. Clinical efficacy will be assessed using the Hamilton Anxiety Rating Scale (HAMA). The neuroimaging substudy will include healthy controls and two groups of patients with GAD receiving SSRI monotherapy with an unchanged medication type and daily dose for at least 2 weeks: an EA group and a sham EA group. Healthy controls will undergo a single resting-state functional MRI (rs-fMRI) scan, whereas patients will undergo scans before and after a single 30-minute EA or sham EA session on the same day. Functional connectivity (FC), regional homogeneity (ReHo), and amplitude of low-frequency fluctuation (ALFF) will be compared between healthy controls and patients before intervention, and pre-to-post changes will be compared between the EA and sham EA groups.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Meet the DSM-5 diagnostic criteria for Generalized Anxiety Disorder (GAD).

• the patient has been taking the same anxiolytic medication consistently for 2 weeks prior to enrollment.

• HAMA score ≥ 14.

• Right-handed(for MRI).

• Aged 18-60 years, with at least primary school education.

• Signed informed consent.

Locations
Other Locations
China
Affiliated Hangzhou First People's Hospital
RECRUITING
Hangzhou
Contact Information
Primary
Lishu Gao
rodelo@sina.com
+86 13858015836
Time Frame
Start Date: 2026-03-10
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 123
Treatments
Experimental: Electroacupuncture (EA) Group
Participants will receive electroacupuncture in addition to SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist.
Sham_comparator: Sham Electroacupuncture (SEA) Group
Participants will receive sham electroacupuncture in addition to SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist.
Active_comparator: Waiting-list (WL) Group
Participants will receive SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist, and will be offered delayed electroacupuncture according to the study protocol.
Related Therapeutic Areas
Sponsors
Leads: Lishu Gao

This content was sourced from clinicaltrials.gov